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Abstract
In melanoma, the presence of promoter related hypermethylation has previously been reported, however, no methylation-
based distinction has been drawn among the diverse melanoma subtypes. Here, we investigated DNA methylation changes
associated with melanoma progression and links between methylation patterns and other types of somatic alterations,
including the most frequent mutations and DNA copy number changes. Our results revealed that the methylome,
presenting in early stage samples and associated with the BRAFV600E mutation, gradually decreased in the medium and late
stages of the disease. An inverse relationship among the other predefined groups and promoter methylation was also
revealed except for histologic subtype, whereas the more aggressive, nodular subtype melanomas exhibited
hypermethylation as well. The Breslow thickness, which is a continuous variable, allowed for the most precise insight
into how promoter methylation decreases from stage to stage. Integrating our methylation results with a high-throughput
copy number alteration dataset, local correlations were detected in the MYB and EYA4 genes. With regard to the effects of
DNA hypermethylation on melanoma patients’ survival, correcting for clinical cofounders, only the KIT gene was associated
with a lower overall survival rate. In this study, we demonstrate the strong influence of promoter localized DNA methylation
changes on melanoma initiation and show how hypermethylation decreases in melanomas associated with less favourable
clinical outcomes. Furthermore, we establish the methylation pattern as part of an integrated apparatus of somatic DNA
alterations.
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Introduction
DNA methylation, along with covalent histone posttranslational
modifications, chromatin remodelling and non-coding RNA-
mediated gene interference, represents an important mechanism
in the integrated apparatus of epigenetic regulation [1,2]. In
addition to playing a role in several physiological processes [3,4,5],
epigenetic mechanisms have been described as key factors in
modifying the accessibility of DNA to transcription factors and,
therefore, in altering the gene expression patterns of several cancer
types [6,7,8]. Given the existence of relatively simple approaches
that require even minute amounts of tumour DNA, the best factor
described involved in melanoma epigenetics is DNA methylation,
a covalent modification of mainly cytosines. The DNA hyper-
methylation is usually strictly localised to the transcriptionally
active gene regions and promoters and directly inhibits gene
expression. In the field of malignant melanoma epigenetics, there
are substantial amounts of data available regarding gene silencing
associated with the localised CpG hypermethylation of specific
gene promoters. However, most of the provided data are derived
from cell lines or were generated using single-gene approaches
[9,10,11,12,13,14]. Despite the fact that some groups have
attempted to conduct array-based experiments, to date, there
are no methylation markers of the diverse melanoma subgroups
based on a stratified analysis with sufficient statistical power [1].
Therefore, having chosen a powerful and high-throughput bead
array technology, we performed array-based experiments to define
the methylation pattern of 1,505 gene promoters. Previous studies
have provided irrefutable proof of the reproducibility of this
approach [6,7,15,16]. The simultaneous detection of transposonal
demethylation and promoter methylation changes should provide
valuable information regarding the molecular mechanisms poten-
tially responsible for the aggressive phenotype of malignant
melanoma. Recently, it has become widely accepted that
Knudson’s two-hit hypothesis is often confirmed through a
combination of differing types of genomic alterations [17,18],
which prompted us to investigate whether methylation patterns
are associated with other types of somatic alterations, such as the
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most frequent mutations (BRAF and NRAS) and DNA copy
number (CN) alterations. Notable previous investigations demon-
strated the prognostic relevance of CN aberrations [19,20,21,22].
Therefore, we also highlighted the cis-and trans-acting CN
alterations of gene expression in malignant melanoma [23].
Moreover, we and others have demonstrated the association of
BRAF and NRAS mutations with CN alterations using BAC
arrays, suggesting a central role of BRAF mutations in gene copy
number changes [21,24,25]. Additionally, a single group reported
that the impact of BRAF signalling on gene methylation is
widespread [26]. Despite the promising initial results, to our
knowledge, no direct, array-based experiments have been
performed in an integrative approach in a wide variety of primary
melanomas. Therefore, we aimed to obtain better insight into how
the DNA methylation changes are associated with distinct somatic
alterations and contribute to melanoma progression.
Materials and Methods
Melanoma samples
Forty-two primary melanomas were included in Illumina bead
assays. The clinicopathological data of the primary melanomas are
summarised in Table 1.
The tumour tissues were obtained from the Department of
Dermatology, University of Debrecen, Hungary. All human
studies were conducted in accordance with the principles outlined
in the Declaration of Helsinki, were approved by the Regional and
Institutional Ethics Committee of the University of Debrecen
Medical and Health Science Centre and were conducted
according to regulations (Protocol #2836–2008). Written in-
formed consent was obtained from each patient. The tumour
diagnoses were made based on formalin-fixed paraffin-embedded
tissue sections using haematoxylin and eosin staining. The
melanoma tumour staging was determined according to the new
melanoma TNM staging system [27].
Genomic DNA and total RNA extraction
After surgical excision, the fresh tissues were immediately placed
in RNA later solution (Applied Biosystems, Foster City, USA), and
high-quality total RNA was prepared from the primary melanoma
tissues using the RNeasy Mini Kit according to the supplier’s
protocol (Qiagen, GmbH, Germany). The obtained RNA
concentrations were measured using a NanoDrop ND-1000 UV-
Vis Spectrophotometer (Wilmington, Delaware, USA). The RNA
sample integrity was determined with the Agilent 2100 Bioanalyser
using the RNA 6000 Nano Kit (Agilent Technologies, Palo Alto,
CA, USA). All RNA samples exhibited a 28S/18S ribosomal RNA
ratio greater than 1.5.
The G-spin Genomic DNA Extraction Kit (Intron, Korea) was
used to isolate high-molecular-weight DNA from primary
melanomas according to the manufacturer’s protocol. To deter-
mine the quantity of DNA obtained, we used a NanoDrop ND-
1000 UV-Vis Spectrophotometer. The DNA integrity was verified
via 1.2% agarose gel electrophoresis.
Bead Assay experiments
The quantitative methylation status of the 1505 CpG sites
corresponding to 807 cancer-related gene promoters was deter-
mined using the Illumina GoldenGate Methylation Assay
(Illumina, San Diego, CA, USA) on bisulphite-treated DNA
samples corresponding to 42 primary melanomas. Bisulphite
treatment was performed on 500 ng DNA using the EZ DNA
Methylation-Gold Kit (Zymo Research). Duplicate samples were
included to measure inter-array reproducibility for quality control.
The GoldenGate assay consists of two allele-specific oligos (ASO)
and two locus-specific oligos (LSO) for each CpG site. Each ASO–
LSO oligo pair corresponds to either the methylated or
unmethylated state of the CpG site. Each methylation CpG spot
is represented by two-color fluorescent signals from the M
(methylated) and U (unmethylated) alleles. BeadStudio version
3.2 (Illumina) was used for obtaining the signal values (Avg-Beta)
corresponding to the ratio of the fluorescent signal from the
methylated allele (Cy5) to the sum of the fluorescents signals of
both methylated (Cy5) and unmethylated alleles (Cy3), 0
corresponding to completely unmethylated sites and 1 to
completely methylated sites. In agreement with the literature, 83
probes corresponding to the sex chromosomes were excluded to
avoid any sex-specific bias [8]. The probes with detection P values
exceeding 0.01 in more than 10% of the specimens were removed
from the analyses to exclude non-biological differences. As Du et
al. performed a systematic comparison between Avg-Beta values
and M-values, which is the logit transformation of Avg-Beta, and
M-values were proven to be statistically valid for conducting
differential methylation analysis [28], M-values were used for class
comparisons, whereas the raw Avg-Beta values were applied for
correlation analyses (see at ‘‘Statistical Analysis’’).
Array CGH for studying copy number alterations
The results data of our previous Tiling Array CGH (HG18
CGH 4672K WG Tiling v2.0) experiments (Roche NimbleGen
core facility, Reykjavik, Iceland) were used which can be found
under the following accession number: E-MTAB-947 (Array
Express Archive repository).
The GISTIC algorithm was used to identify regions containing
a statistically high frequency of copy number aberrations
compared to the ‘‘background’’ aberration frequency. This
function is most appropriate for cancer samples, as it was designed
using a cancer dataset [29]. After the gain/loss aberrations were
identified in each sample, a statistic (the G score) was calculated for
each aberration. This G score is a measure of the frequency of
occurrence of the aberration and the magnitude of the copy
number change (log ratio intensity) at each location in the
aggregate of all samples in the dataset. Each location is scored
separately for gains and losses. The locations in each sample are
permuted, simulating data with random aberrations, and this
random distribution is compared to the observed statistic to
identify scores that are unlikely to occur by chance alone.
Array CGH results were verified using four colour FISH (Abott
Molecular Inc., USA). The FISH experiments were performed
according to the Suppliers’ protocol and visualized by Zeiss Axio
Imager Confocal Microscopy.
Quantitative RT-PCR
The expression status of selected genes (FGFR3, MCAM and
IL8) was measured using quantitative real-time PCR with the ABI
Prism 7900HT Sequence Detection System (Applied Biosystems,
Carlsbad, California, USA). Reverse transcription (RT) was
carried out on total RNA (600 ng) using the High Capacity
cDNA Archive Kit, according to the protocol of the supplier
(Applied Biosystems, Carlsbad, California, USA). Predesigned
TaqMan Gene Expression Assays (Applied Biosystems, Carlsbad,
California, USA) were used to perform qPCR for the above-
mentioned 3 genes.
Statistical analyses
The effect of localised methylation on clinical predictors,
BRAFV600E mutation and patient survival. We applied
random variance t-statistics on all the binary data classes such as
DNA Methylation in Primary Melanomas
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e96612
Breslow thickness with the cut-off value of 4 mm; metastasis,
ulceration and histologic subtype. Being continuous variable,
Breslow thickness can be divided into more subgroups: according
to the TNM system up to 5 groups can be created, however, due to
the limitation of smaller samples, developing 3 groups based on the
cut-off values of 2 mm and 4 mm were the most ideal. F-statistics
was applied on the trichotomised Breslow groups for each CpG
site.
CpG sites were considered differentially methylated when their
p values based on univariate t-tests or f-tests were less than 0.01; in
addition, given CpG sites were identified differentially methylated
between the melanoma subgroups based on a multivariate
permutation test providing 90% confidence that the false discovery
rate was less than 20%. Volcano plots were applied to illustrate
differential methylation patterns among clinical subgroups of
melanomas (the clinicopathological characteristics of melanomas
are summarized in Table 1). Volcano plots combine p-values of
the t-tests for each CpG sites and ratios between the melanoma
subgroups. Additionally, the trichotomised Breslow thickness
groups were visualized by heatmap and compared by Principal
Component Analysis (PCA).
For the aforementioned class comparisons, M-values, the logit
transformations of signal intensities were used.
To evaluate the KEGG-based gene networks disturbed by DNA
methylation, we applied the Efron-Tibshirani Gene Set Analysis
that uses ‘maxmean’ statistics to identify gene sets expressed
differentially among predefined classes [30]. The threshold for
determining significant gene sets was 0.01 in each approach.
The Cox proportional univariate approach was performed on
each gene to test whether the methylation status of a particular
gene significantly influences the survival at the p,0.05 level. To
control for covariates on survival and to predict the survival risk,
the Supervised Principal Components method was used.
As normal tissues were not involved in or studies we used
external dataset from the study of Conway et al. involved 27 naevi
[15] to check the methylation status of a given gene in control
tissues.
Remaining statistics were performed using SPSS 19.0 and
GraphPad Prism 6.0 demo version. Venn diagram was made by
VENNY, an interactive tool for comparing lists with Venn
Diagrams developed by Oliveros, J.C. (2007). The tool is available
at: http://bioinfogp.cnb.csic.es/tools/venny/index.html.
Relationship between methylation patterns and copy
number alterations. We studied how DNA copy number
changes and methylation pattern associated within the same
genetic loci. For this purpose, the copy number and localised
methylation data of the corresponding genomic regions were
simultaneously analysed gene-by-gene using CGH Tools, and
Pearson’s correlation was performed with p,0.01 after correction
for multiple testing. Additionally, Fisher’s exact test was applied to
identify the genome sequences where gene methylation occurs
frequently.
Results
Methylation patterns of melanoma subgroups
Our experimental design for applying the Illumina Bead Assay
included two replicate samples among arrays to measure the inter-
array reproducibility. Technical replicates were significantly
correlated with each other by Pearson’s correlation (Replicate
#1: r2 = 0.95, p,0.001; Replicate #2: r2 = 0.98, p,0.001).
After the initial filtering process, 895 CpG sites were available
for further analyses and M-values, logistically transformed Avg-
Beta values, were used for statistical approaches.
Our main goal was to investigate the relationship between the
distinct biological types of melanomas and the promoter methyl-
ation levels. As the multivariate permutation test provides a tight
probabilistic control on the proportion of false discoveries, this test
was used for class comparison on each predefined subgroup (the
clinical subgroups of primary melanomas are detailed in Table 1)
according to the following criteria: CpG sites were considered
differentially methylated when their p values were less than 0.01
and FDR rates were below 0.2.
Figure 1A demonstrates that relatively large number of CpG
sites was found to be differentially methylated between melanoma
Table 1. Clinical-pathological parameters of primary
melanomas.
Variables


































BRAFV600E wild type 24
1Superficial spreading melanoma.
2Nodular melanoma.
3Thickness categories are based on the current staging system.
4Thickness categories are based on the current staging system.
5Metastasis of the examined primary tumours.
6Patients with at least a 5-year follow-up period were included.
doi:10.1371/journal.pone.0096612.t001
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Figure 1. Methylation patterns of primary melanomas associated with known clinical predictors. (A) Volcano plots of differentially
methylated genes associated with known predictors. Blue dots indicates decreased and red indicates increased methylation as follows: Breslow
thickness: 51 hypomethylated probes (43 individual genes) and 5 hypermethylated probes (5 individual genes); metastatic capacity: 23
hypomethylated probes (21 individual genes) and 5 hypermethylated probes (4 individual genes), ulceration: 48 hypomethylated probes (43
DNA Methylation in Primary Melanomas
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subgroups. Interestingly, the majority of these CpGs were
characterised by decreased DNA methylation levels in samples
with poor prognosis (larger than 4 mm, metastatic, ulcerated and
nodular primary melanomas). Histologic subtype exhibited a more
disturbed methylation pattern involving high number of differen-
tially methylated genes in both superficial and nodular subtype. As
it can be seen in Figure 1A, some of the differentially methylated
individual genes were represented by more than one significant
CpG sites arguing in favour of the consistency of given alterations.
Altogether, 111 differentially methylated genes were identified in
the context of aforementioned clinical predictors: 43 individual
genes were hypermethylated and 68 genes hypomethylated in
melanomas with less favourable clinical outcome. The differen-
tially methylated gene lists specific for the Breslow thickness,
ulceration, metastatic capacity and histologic subtype are detailed
in Table S1. Venn diagrams (Figure 1B) indicate the common
properties among genes with decreased and increased DNA
methylation, respectively.
Being a continuous variable, Breslow thickness allowed the most
precise insight into how methylation pattern changes across
melanoma stages. In Figure 2A, the heatmap horizontally shows
the primary melanoma samples with distinct Breslow thicknesses.
The intensive hypermethylation of 45 CpGs is marked with brown
colour in the early stage tumours (Breslow thickness ,2 mm), and
this hypermethylation decreases during the medium and advanced
stages. Low-level methylation values are represented with yellow
colour. In other types of cancer, hypermethylation has been shown
to be associated with tumour progression. Interestingly, the
hypermethylation patterns of 45 CpGs, which are detected in
the early stages of melanomas, gradually decrease in the medium
individual genes) and 8 hypomethylated probes (8 individual genes), histologic subtype: 28 hypomethylated probes (26 individual genes) 23
hypermethylated probes (20 individual genes) (B) A Venn diagrams indicate the overlap of differentially methylated genes (in left: number of
hypomethylated genes; in right: number of hypermethylated genes) for each clinical predictor class.
doi:10.1371/journal.pone.0096612.g001
Figure 2. Hypermethylation is an early event in melanomas and decreases with tumour thickness. (A) The heatmap demonstrates the
hypermethylation patterns (indicated in brown colour) of 45 CpGs, which can be detected in the early stages of melanomas (horizontal purple colour)
but decrease from the medium stage (horizontal green colour) to the late stage (horizontal blue colour). (B) The principal component analysis for the
distinction of the Breslow thickness the sample groups (large: blue dots; medium: green dots; and small melanoma samples: purple dots) based on
the 45 differentially methylated CpGs. The analysis revealed that, according to the first three components, which covered the 56% of the total
variance, the three groups were significantly different (p,0.05)
doi:10.1371/journal.pone.0096612.g002
DNA Methylation in Primary Melanomas
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stages and almost disappear in late stages of the disease. The
Principal Component Analysis (Figure 2B) clearly demonstrated
that, according to the pattern of the 45 hypermethylated CpGs,
the melanoma groups were significantly separated.
It is important to note that normal tissues were not used in our
experiments. However, such datasets can be found in the
literature, and we were therefore able to correct for the
methylation status of normal naevi specimens (see Materials and
Methods). These results thus argue that the hypermethylation of
the 45 CpGs occurs early, in melanomas less than 2 mm, and then
decreases during melanoma progression.
In addition to individual gene signatures, we aimed to
determine whether the perturbed KEGG-based gene networks
are related to localised methylation patterns. We identified
differentially methylated genes belongs to Cell cycle pathways in
primary melanomas with metastatic capacity. Genes associated at
Leukocyte signalling were also demonstrated to be differentially
methylated in ulcerated samples (Figure 3A). Interestingly, Cell
communication and ECM-receptor interaction networks were
found to be significant at the 0.01 level between BRAFV600E
mutant and wild type samples, notwithstanding the fact that, we
were unable to find differentially methylated CpGs at the
individual gene level (Figure 3A–B). The full list of CpG probes
is given in Table S2. There was poor overlap (Figure 3C) between
the differentially methylated genes associated with BRAFV600E
mutation and clinical subgroups discussed above.
Our analysis of the effects of hypermethylation on patient
survival identified an association between six hypermethylated
genes (DSP, EPHB6, HCK, IL18, IRAK3 and KIT) with lower
OS values. Four of the six genes (DSP, HCK, IL18 and KIT)
exhibited significantly different Kaplan-Meier curves (Figure 4).
However, when we included patient age, gender and BRAFV600E
mutation status in the survival risk prediction model, only the KIT
gene remained significant.
Analysis of the mRNA expression level of the
differentially methylated genes identified in melanoma
Three genes among the differentially methylated panel were
chosen to measure mRNA expression levels by qPCR (FGFR3,
MCAM and IL8) according to the following selection criteria: we
exclusively focused on genes that had not been previously referred
to as methylated in melanomas; furthermore, FGFR3 was chosen
in the context of histologic subtype and MCAM of Breslow
thickness, while IL8, being a commonly methylated gene among
distinct clinical groups was measured across in all categories
(Breslow thickness, histologic subtype, ulceration and metastatic
capacity).
Inverse relationships were found between hypermethylation and
mRNA expression regarding FGFR3, MCAM and IL8 as well,
Figure 3. Differentially methylated gene sets between the BRAFV600E mutant and wild-type classes. (A) Differentially methylated gene
sets between BRAFV600E mutant and wild-type, metastatic and non-metastatic, ulcerated and non-ulcerated classes according to the Kyoto
Encyclopaedia of Genes and Genomes. (B) Average log-ratios of methylation intensities in BRAFV600E mutant and wild-type melanomas. Red indicates
significant genes associated with ECM-receptor interaction and blue depicts significant genes on Cell communication pathway. (Eleven genes overlap
between the ECM-receptor interaction and Cell communication.) (C) Venn diagram shows lack of overlap between differentially methylated genes
associated with BRAFV600E mutation and the known clinical predictors as Breslow thickness, metastatic capacity, ulceration and histologic subtype.
doi:10.1371/journal.pone.0096612.g003
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supporting the notion that the methylation pattern are functionally
relevant to gene expression. Significant (p,0.05) MCAM mRNA
expression level differences were revealed between smaller
(Breslow thickness #4 mm) and larger (Breslow thickness .
4 mm) melanomas. IL8 expression differed as well between sample
distinct categories of Breslow thickness, melanoma surface
ulceration and metastatic capacity. The qPCR and corresponding
correlation results are summarised in Figure 5.
Coincidence of localised hypermethylation and copy
number alterations
We determined the frequent copy number gains and losses
associated with the BRAFV600E mutation (Figure 6A) and Breslow
thickness (Table S3) in primary melanomas. As expected, a set of
marked copy number alterations was associated with both the
BRAFV600E (Figure 6A) mutation and Breslow thickness (Table S3)
categories.
In the BRAFV600E mutant samples, significant CN losses
(Figure 6B) were found at in the 1p, 1q, 2p, 4q, 6q, 7p, 9p, 9q,
10p, 10q, 11p, 14p, 15p, 17p, 20p and 21p regions, whereas CN
gains (Figure 6C) were detected across chromosomes 1q, 6p, 7p,
7q, 8q, 11q, 15q, 20q and 22q.
In the late stages of primary melanomas (Breslow thickness .
4mm), significant CN losses were observed more frequently and
comprised deletions of 1p, 4q, 7p, 9p, 14p and 21p, whereas CN
gains were only observed in the 11q region, as summarised in
Table S3. Despite not reaching a significant level, it is worth
noting that the CN losses in 19p12 (harbouring the DNA
Methyltransferase-1 gene) were exclusively associated with more
advanced stages (Breslow thickness .2mm; Figure S1A). Howev-
er, among the late-stage samples (Breslow thickness .4mm), CN
gains were also found with CN losses in some samples. Figure
S1B–D represents late-stage melanomas that exhibited CN losses
in 19p12.
In addition to the general mapping of the CN-altered genomic
regions, we quantitatively assessed the coincidence of CN
alteration and methylation patterns gene by gene. Similar to
other studies, we established gene level measurements by
averaging the methylation states within gene-specific regions. As
significantly and positively correlated genes were revealed at the
levels of methylation and CN alteration, the correlations cannot
possibly represent coordinated allele loss and hypermethylation;
nevertheless, these results do not remain significant after the
multiple correction procedure. Moreover, direct correlation often
involves genome parts that are positively correlated at the level of
methylation and CN without detected CN changes or altered
methylation. Therefore, we applied an alternative approach based
on the frequency of methylated genes harbouring significant CN
alterations to test Knudson’s two-hit hypothesis. As indicated in
Figure 6A, 6q12–6q25.1 comprises a relatively large, significant
CN loss and two hypermethylated genes, namely, EYA4 (6q23) and
MYB (6q22–q23). When measured quantitatively, a significant
Figure 4. Hypermethylated genes associated with decreased survival rate in melanoma patients. The Kaplan-Meier curves for genes
(DSP, EPHB6, HCK, IL18, IRAK3 and KIT) whose hypermethylation was associated with a lower overall survival rate (OS); the Cox proportional univariate
approach was performed on each gene to test whether a methylation status of a particular gene significantly influences the survival at the p,0.05
level.
doi:10.1371/journal.pone.0096612.g004
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inverse correlation was observed between CN loss and DNA
hypermethylation (Figure 6 D–E).
Array CGH results were further confirmed by four colour FISH
experiments specific for 11q13 (specific for CCND1 gene), 6p25
(specific for RREB1 gene), 6q23 (specific for MYB gene) and
centromere 6 on 27 primary melanomas (Figure 7A–C).
Discussion
Among epigenetic aberrations, DNA methylation itself features
a diverse presence [31]. Recently, 5-hydroxymethylcytosine (5-
hmC) has been identified as a constituent of mammalian DNA and
described as the sixth base of the genome [32]. The loss of 5-hmC
has been highlighted as a hallmark of melanoma by a single,
remarkable study, whereas interesting clues as to the role of 5-
hydroxymethylcytosine are still emerging [33]. In contrast to 5-
hmC, the importance of 5-methylcytosine (5-mC) in cancer cells is
much more firmly established [1,34]. Aberrant promoter DNA
hypermethylation or localised methylation preferably occurs in
CpG dinucleotide-dense regions, resulting in the down-regulation
of the corresponding gene [1,14].
It has recently become apparent that malignant melanomas
feature hypermethylation, and currently more than 80 genes –
mainly in promoter regions – are hypermethylated at a single-gene
level [1,12,31]. Taking a global view of the available data, the
number of primary tumour samples involved in the studies and the
frequency of positive results do not allow determining whether the
hypermethylated genes described are appropriate for diagnosis or
can be considered candidate therapeutic targets. Moreover, most
of the data provided are derived from cell lines and estimated
methylation values indirectly consisting of three steps: measuring
mRNA or protein expression in cell lines, treating samples with a
specific drug that acts against the process of methylation and
measuring gene expression again. Nonetheless, powerful argu-
ments have been presented in the literature that support direct
experiments being less ambiguous; furthermore, most of the
groups conducting direct measurements have applied candidate
gene approaches [31,35].
In addition to the rapid progress that has been made in studying
promoter hypermethylation at the single-gene level, only two
groups have attempted to conduct array-based experiments to
identify the methylation pattern of thousands of gene promoters
[15,36]. Regrettably, one group has focused only on comparing
Figure 5. Relationship between gene expression and DNA methylation. The gene expressions of MCAM, FGFR3 and IL8 were measured by
qRT-PCR and are presented as bars (fold change in left Y axis), and Avg-Beta methylation values are demonstrated as lines (shown in right Y axis).
Methylation data was extracted from Illumina bead assay, with distinct probes represented as different lines. Gene expression differences among the
groups were analysed using the Mann-Whitney test, which revealed significant differences for the MCAM and IL8 genes.
doi:10.1371/journal.pone.0096612.g005
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the methylation level of primary invasive melanomas with benign
melanocytes and has clearly identified a group of genes in a
statistically powerful interpretation that can be used to discrim-
inate naevi from melanomas based on their methylation signature
[15]. Another group has examined the short-term cultures of
homogeneous stage III specimens [36].
As no data are currently available regarding the methylation
markers of diverse melanomas with different clinical behaviours,
Figure 6. Coincidence of DNA copy number (CN) alterations and hypermethylation. (A) The distribution of CN aberrations (red indicates
CN losses and blue indicates CN gains on the frequency plot) specific for the BRAFV600E mutant (purple line on the left) and BRAFV600E wild-type
(green line on the left) primary melanomas. The methylated genes are shown as blue lines in the lower part of the figure, and the red dotted circle
highlights 6q23 as the only region where a coincidence was revealed. The significant CN alterations are highlighted in grey in the upper part of the
figure. Frequent CN losses (B) and CN gains (C) are given based on the G-score of GISTIC algorithm, which is a measure of the frequency of
occurrence of the aberration and the magnitude of the CN alteration at each location in the aggregate of all samples in the dataset. The locations of
the alterations in each sample are permuted, simulating data with random aberrations, and the significance is represented as Q-Bounds. Grey lines
indicate the peak, whereas the grey shaded area is an extended peak based on leave-one-out algorithm to allow for errors in the boundaries in a
single sample. (C) Correlation plot for CN alterations and DNA methylation regarding the MYB gene and (D) the EYA4 gene.
doi:10.1371/journal.pone.0096612.g006
DNA Methylation in Primary Melanomas
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we performed a systematic comparison of localised methylation
patterns among 42 primary melanomas using the Illumina Golden
Gate Cancer Panel Bead Assay. We found 111 differentially
methylated CpGs altogether among melanoma subgroups and the
majority of CpG sites were hypermethylated in melanomas that
represent more favourable prognoses including a non-ulcerated
tumour surface, superficial spreading histological subtype, non-
metastatic subgroup and smaller tumour thickness (Breslow
thickness ,2 mm). Regarding more advanced-stage specimens,
the hypermethylome detected in melanomas that represents better
prognoses markedly decreased. The decrease in the methylation
levels occurred gradually, as the continuous Breslow thickness
variables allowed us to distinguish more than two groups among
primary melanomas and to map the progress of demethylation
during distinct stages (Breslow thickness ,2 mm; Breslow
thickness 2–4 mm; Breslow thickness .4 mm). The genes
involved in demethylation partially overlap among clinical
subgroups: five genes (EMR3, SEPT9, IL8, MMP14 and
SLC22A18) were found to be commonly demethylated in large
(Breslow thickness .4 mm), nodular subtype, ulcerated and
metastatic melanomas. The SEPT9 gene is an ovarian tumour
suppressor playing a role in cell cycle control [37]; IL8 gene
expression is elevated in metastatic melanomas and can increase
the level of MMP2 [38]; SLC22A18 has been reported to be
down-regulated due to promoter hypermethylation in gliomas
[38,39]; MMP14 has not been found to play a role in melanoma
progression thus far. Among the aforementioned clinical groups,
the largest similarity (27 overlapping genes) has been detected
between the demethylated genes associated with Breslow thickness
and ulceration. The histologic subtype represents the most unique
methylation pattern, comprising 30 differentially methylated genes
between superficial and nodular melanomas.
Our results contrast those of studies describing the hypermethy-
lation patterns of specific genes as tumour progression-related
markers based on single gene approaches. However, Conway et al.
supported the claim that a covalent change from cytosine to 5-
methylcytosine in the promoter region occurs as an early
aberration event in melanomas [15]. Notwithstanding, their
results highlighted not only the hypermethylated but also the
demethylated genes in heterogeneous melanomas compared to
naevi. This group reported a lack of similarity – involving only two
genes, namely, RUNX3 and SYK – with the previously published
data.
Previously, a group published two independent studies regard-
ing in vitro data that demonstrated how the BRAFV600E mutation
causes widespread alterations in DNA methylation [26,40]. Along
with Hou et al., we found hypermethylated CpGs accompanied by
the BRAFV600E mutation in primary melanomas. In agreement
with these observations, we also found distinct methylation pattern
in BRAFV600E mutant primary melanomas involving genes of Cell
Communication and ECM-receptor interaction networks. A
similar association between the BRAFV600E mutation and DNA
methylation was described in colon cancer, as methylated samples
convincingly represented a distinct subset encompassing almost all
cases of tumours with the BRAFV600E mutation [41]. A
remarkable study performed by Roon et al. revealed the
BRAFV600E mutation-specific hypermethylation of CpG regions
in colon cancer samples by Differential Methylation Hybridization
on high-density oligonucleotide microarrays [42]. Interestingly,
the authors identified several cancer-related pathways, including
the PI3 kinase and Wnt signalling pathways being differentially
methylated between BRAFV600E mutant and wild type samples.
Additionally, the group found the silencing of FOXD3 hypermethy-
lated manner. Based on these studies, authors suggest that a specific
epigenetic pattern can contribute to a favourable context for the
acquisition of BRAFV600E mutations [42]. However, further studies
are warranted to further clarify the relationship between the
mutation and DNA methylation.
In addition to the common mutations, specific patterns of CN
alterations have been reported in melanomas characteristic of
unfavourable clinical outcomes [21]. Furthermore, it has become
obvious that BRAFV600E mutated melanomas display distinct
patterns for CN changes, providing the first line of evidence in
support of Knudson’s two-hit hypothesis [19,21]. However, none
of the published studies attempted to evaluate the relationship
between CN alterations and DNA methylation in melanomas.
Our group performed a Tiling Array CGH, and, apart from
highlighting common CN losses and amplification in the
subgroups of primary melanomas, we demonstrated that 6q12–
6q25.1 comprises a remarkable CN loss, harbouring two
hypermethylated genes on 6q23, EYA4 and MYB1. This result
was measured and verified quantitatively and provides evidence
for Knudson’s two-hit hypothesis at the level of CN loss and DNA
hypermethylation. Notably, MYB1 is an important discriminator
between melanomas and naevi, as validated by FISH in 123
melanomas and 110 naevi [43,44]. The copy number deletion of
MYB1 is currently used in the diagnosis of melanoma.
Our Tiling Array CGH experiments showed another important
feature: the CN alterations of chromosome 19 were only detected
in advanced staged primary melanomas. Notably, the altered
genomic regions encompass 19p13.2, which harbours the
DNMT1 gene (DNA Methyltransferase-1), which plays a role in
the establishment and regulation of tissue-specific patterns of
methylated cytosine residues [31]. The DNA CN alterations of
DNMT1 in advanced stages primary melanomas raise crucial
questions: Is demethylation, contributing to clinical outcomes, only
a passive consequence of CN loss? Or do CN alterations – as was
demonstrated in the context of epigenetic mechanisms and the
BRAFV600E mutation – directly control the DNA methylation
changes to influence the gene expression patterns of given
molecules? Regardless of the reason for changes in methylation,
we obtained better insight into how gene expression levels are
regulated by DNA methylation: demethylation was associated with
increased mRNA levels, whereas hypermethylation was associated
with decreased levels.
In summary, we demonstrated the strong influence of DNA
methylation changes on melanoma progression. However, hyper-
methylation, which has been greatly emphasised in the literature,
appears to represent more complexity both in melanoma initiation
and progression. Additionally, the inhibition of promoter hyper-
methylation might represent the most promising therapeutic target
for the treatment of melanoma, and several types of DNMT
inhibitors are currently being developed [35]. Considering the
Figure 7. FISH analysis to confirm array CGH results. CN alteration at specific regions of a representative BRAFV600E mutant primary melanoma:
(A) CN gains were revealed at chromosome 6p while CN losses occurred at chromosome 6q in BRAFV600E samples. (B) High level CN gain was seen at
the region of 11q13–q14. (C) Four colour FISH was performed to verify the CN altered genomic regions: green fluorescence (gain of CCND1 gene on
11q13), yellow fluorescence (loss of MYB gene on 6q23), red fluorescence (gain of RREB1 gene on 6p25), whereas blue fluorescence indicates
centromere 6.
doi:10.1371/journal.pone.0096612.g007
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dual role of DNA methylation, further efforts are needed to
investigate the importance of such drugs in melanoma treatment.
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Figure S1 Copy number alteration of chromosome 19 in
Breslow thickness . 4 mm melanomas. (A) The Tiling
Array CGH revealed characteristic CN differences among the
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2 mm; yellow line: Breslow thickness 2–4 mm; red line: Breslow
thickness .4 mm) regarding the CN alterations of chromosome
19. The CN-altered regions involve 19p13.2 harbouring the
Methyltransferase-1 gene (DNMT1). Panels (B–E) depict repre-
sentative figures of CN losses revealed exclusively in medium- or
advanced-stage (according to Breslow thickness) primary melano-
mas.
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